The merger between Oneness Biotech and Fountain Biopharma makes the pipeline and resources integrated. The pipeline will include a late-stage drug to be launched in global market as well as new drugs in earlier clinical stage in immunology. This merger will strengthen the R&D capability in favor of global collaboration and competition.